The biomarker bill has now won passage in both houses of the Kentucky General Assembly. The House bill garnered overwhelming support in the Senate Monday. The bill requires insurance coverage of biomarker technology used to develop specific treatment plans, often for cancer. Senate President Robert Stivers called it, quote, “one of the better bills we’ll do this session.”
“This past year I would assume or suggest that probably a third of my conversations with people in the healthcare industry are related to biomarkers,” said Stivers.
